Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 13(1): 9333, 2023 06 08.
Article in English | MEDLINE | ID: mdl-37291185

ABSTRACT

Mortality of Duchenne Muscular Dystrophy (DMD) is a consequence of progressive wasting of skeletal and cardiac muscle, where dystrophinopathy affects not only muscle fibres but also myogenic cells. Elevated activity of P2X7 receptors and increased store-operated calcium entry have been identified in myoblasts from the mdx mouse model of DMD. Moreover, in immortalized mdx myoblasts, increased metabotropic purinergic receptor response was found. Here, to exclude any potential effects of cell immortalization, we investigated the metabotropic response in primary mdx and wild-type myoblasts. Overall, analyses of receptor transcript and protein levels, antagonist sensitivity, and cellular localization in these primary myoblasts confirmed the previous data from immortalised cells. However, we identified significant differences in the pattern of expression and activity of P2Y receptors and the levels of the "calcium signalling toolkit" proteins between mdx and wild-type myoblasts isolated from different muscles. These results not only extend the earlier findings on the phenotypic effects of dystrophinopathy in undifferentiated muscle but, importantly, also reveal that these changes are muscle type-dependent and endure in isolated cells. This muscle-specific cellular impact of DMD may not be limited to the purinergic abnormality in mice and needs to be taken into consideration in human studies.


Subject(s)
Calcium , Muscular Dystrophy, Duchenne , Mice , Humans , Animals , Mice, Inbred mdx , Calcium/metabolism , Muscular Dystrophy, Duchenne/genetics , Muscular Dystrophy, Duchenne/metabolism , Myoblasts/metabolism , Calcium Signaling , Myocardium/metabolism , Receptors, Purinergic/metabolism , Muscle, Skeletal/metabolism
2.
Sci Rep ; 11(1): 11144, 2021 05 27.
Article in English | MEDLINE | ID: mdl-34045551

ABSTRACT

E. coli purine nucleoside phosphorylase is a homohexamer, which structure, in the apo form, can be described as a trimer of dimers. Earlier studies suggested that ligand binding and kinetic properties are well described by two binding constants and two sets of kinetic constants. However, most of the crystal structures of this enzyme complexes with ligands do not hold the three-fold symmetry, but only two-fold symmetry, as one of the three dimers is different (both active sites in the open conformation) from the other two (one active site in the open and one in the closed conformation). Our recent detailed studies conducted over broad ligand concentration range suggest that protein-ligand complex formation in solution actually deviates from the two-binding-site model. To reveal the details of interactions present in the hexameric molecule we have engineered a single tryptophan Y160W mutant, responding with substantial intrinsic fluorescence change upon ligand binding. By observing various physical properties of the protein and its various complexes with substrate and substrate analogues we have shown that indeed three-binding-site model is necessary to properly describe binding of ligands by both the wild type enzyme and the Y160W mutant. Thus we have pointed out that a symmetrical dimer with both active sites in the open conformation is not forced to adopt this conformation by interactions in the crystal, but most probably the dimers forming the hexamer in solution are not equivalent as well. This, in turn, implies that an allosteric cooperation occurs not only within a dimer, but also among all three dimers forming a hexameric molecule.


Subject(s)
Escherichia coli/genetics , Mutation , Purine-Nucleoside Phosphorylase/genetics , Tryptophan/genetics , Binding Sites , Escherichia coli/metabolism , Models, Molecular , Protein Conformation , Purine-Nucleoside Phosphorylase/metabolism
3.
Am J Pathol ; 190(1): 190-205, 2020 01.
Article in English | MEDLINE | ID: mdl-31726040

ABSTRACT

Duchenne muscular dystrophy (DMD) causes severe disability and death of young men because of progressive muscle degeneration aggravated by sterile inflammation. DMD is also associated with cognitive and bone-function impairments. This complex phenotype results from the cumulative loss of a spectrum of dystrophin isoforms expressed from the largest human gene. Although there is evidence for the loss of shorter isoforms having impact in the central nervous system, their role in muscle is unclear. We found that at 8 weeks, the active phase of pathology in dystrophic mice, dystrophin-null mice (mdxßgeo) presented with a mildly exacerbated phenotype but without an earlier onset, increased serum creatine kinase levels, or decreased muscle strength. However, at 12 months, mdxßgeo diaphragm strength was lower, whereas fibrosis increased, compared with mdx. The most striking features of the dystrophin-null phenotype were increased ectopic myofiber calcification and altered macrophage infiltration patterns, particularly the close association of macrophages with calcified fibers. Ectopic calcification had the same temporal pattern of presentation and resolution in mdxßgeo and mdx muscles, despite significant intensity differences across muscle groups. Comparison of the rare dystrophin-null patients against those with mutations affecting full-length dystrophins may provide mechanistic insights for developing more effective treatments for DMD.


Subject(s)
Calcinosis/pathology , Dystrophin/metabolism , Fibrosis/pathology , Macrophages/immunology , Muscular Dystrophy, Animal/pathology , Muscular Dystrophy, Duchenne/pathology , Vascular Calcification/pathology , Animals , Calcinosis/immunology , Calcinosis/metabolism , Dystrophin/genetics , Fibrosis/immunology , Fibrosis/metabolism , Inflammation , Macrophages/metabolism , Male , Mice , Mice, Inbred mdx , Muscle, Skeletal/immunology , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Muscular Dystrophy, Animal/immunology , Muscular Dystrophy, Animal/metabolism , Muscular Dystrophy, Duchenne/immunology , Muscular Dystrophy, Duchenne/metabolism , Vascular Calcification/immunology , Vascular Calcification/metabolism
4.
Biochim Biophys Acta Mol Basis Dis ; 1865(6): 1138-1151, 2019 06 01.
Article in English | MEDLINE | ID: mdl-30684640

ABSTRACT

Pathophysiology of Duchenne Muscular Dystrophy (DMD) is still elusive. Although progressive wasting of muscle fibres is a cause of muscle deterioration, there is a growing body of evidence that the triggering effects of DMD mutation are present at the earlier stage of muscle development and affect myogenic cells. Among these abnormalities, elevated activity of P2X7 receptors and increased store-operated calcium entry myoblasts have been identified in mdx mouse. Here, the metabotropic extracellular ATP/UTP-evoked response has been investigated. Sensitivity to antagonist, effect of gene silencing and cellular localization studies linked these elevated purinergic responses to the increased expression of P2Y2 but not P2Y4 receptors. These alterations have physiological implications as shown by reduced motility of mdx myoblasts upon treatment with P2Y2 agonist. However, the ultimate increase in intracellular calcium in dystrophic cells reflected complex alterations of calcium homeostasis identified in the RNA seq data and with significant modulation confirmed at the protein level, including a decrease of Gq11 subunit α, plasma membrane calcium ATP-ase, inositol-2,4,5-trisphosphate-receptor proteins and elevation of phospholipase Cß, sarco-endoplamatic reticulum calcium ATP-ase and sodium­calcium exchanger. In conclusion, whereas specificity of dystrophic myoblast excitation by extracellular nucleotides is determined by particular receptor overexpression, the intensity of such altered response depends on relative activities of downstream calcium regulators that are also affected by Dmd mutations. Furthermore, these phenotypic effects of DMD emerge as early as in undifferentiated muscle. Therefore, the pathogenesis of DMD and the relevance of current therapeutic approaches may need re-evaluation.


Subject(s)
Adenosine Triphosphate/metabolism , Calcium Signaling/genetics , Gene Expression Profiling/methods , Myoblasts/metabolism , Receptors, Purinergic P2Y2/genetics , Uridine Triphosphate/metabolism , Adenosine Triphosphate/pharmacology , Animals , Calcium/metabolism , Calcium Signaling/drug effects , Cell Movement/drug effects , Cell Movement/genetics , Cells, Cultured , Dystrophin/genetics , Dystrophin/metabolism , Gene Ontology , Mice , Mice, Inbred mdx , Muscular Dystrophy, Duchenne/genetics , Muscular Dystrophy, Duchenne/metabolism , Muscular Dystrophy, Duchenne/pathology , Mutation , Myoblasts/cytology , Myoblasts/drug effects , Receptors, Purinergic P2Y2/metabolism , Uridine Triphosphate/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...